Trial result ·
Efficacy of Reticulocyte Haemoglobin Equivalent-Guided Versus Transferrin Saturation-Guided Iron Supplement Protocol in Haemodialysis Patients: A Multicenter Cluster Randomized Controlled Trial.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This trial looked at iron given into a vein for people on dialysis. A usual blood test, called TSAT, can guide iron doses. This trial tested a lower-cost blood test called RET-He. In total, 160 people on dialysis took part. Groups were split by chance to use TSAT or RET-He. The TSAT group had 79 people, and the RET-He group had 81.
What they found
The main goal was a score called ERI. This score shows how poorly the body responds to erythropoietin. At 3 months, RET-He was not worse than TSAT on this score. The same held true at 6 months. The RET-He group was given less iron in total. Deaths, hospital stays, heart events, transfusions and infections did not clearly differ.
What it means for patients
The authors conclude RET-He was not worse than TSAT over 6 months. They say RET-He may offer a cheaper way to manage anaemia. They add it may be easier to get than other iron tests. They note this may help in particular where resources are low.
Why it is not certain yet
The trial was not designed to test deaths, hospital stays or infections. So the lack of a clear difference in these is not firm. The abstract gives results only up to 6 months. The abstract does not give side effects for each group.
Source
Efficacy of Reticulocyte Haemoglobin Equivalent-Guided Versus Transferrin Saturation-Guided Iron Supplement Protocol in Haemodialysis Patients: A Multicenter Cluster Randomized Controlled Trial.
PubMed · PMID 42477910We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Iron deficiency anaemia publications